{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Dermatologic+Disorders&page=44", "query": { "condition": "Dermatologic Disorders", "page": 44 }, "page_size": 10 }, "pagination": { "page": 44, "page_size": 10, "total_count": 13615, "total_pages": 1362, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Dermatologic+Disorders&page=45&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Dermatologic+Disorders&page=43&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-31T11:27:40.017Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04191135", "title": "Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple Negative Breast Cancer (TNBC) (MK-7339-009/KEYLYNK-009)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Triple Negative Breast Neoplasms" ], "interventions": [ { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Olaparib", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 462, "start_date": "2019-12-19", "completion_date": "2025-11-26", "has_results": true, "last_update_posted_date": "2026-09-14", "last_synced_at": "2026-10-31T11:27:40.017Z", "location_count": 25, "location_summary": "Monterey, California • San Francisco, California • Santa Monica, California + 20 more", "locations": [ { "city": "Monterey", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Santa Rosa", "state": "California" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04191135" }, { "nct_id": "NCT00645333", "title": "Phase I/II Study of MK-0752 Followed by Docetaxel in Advanced or Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Breast Cancer" ], "interventions": [ { "name": "MK-0752, Docetaxel, Pegfilgrastim", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Michigan Rogel Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2008-03", "completion_date": "2012-10", "has_results": true, "last_update_posted_date": "2014-04-04", "last_synced_at": "2026-10-31T11:27:40.017Z", "location_count": 3, "location_summary": "Boston, Massachusetts • Ann Arbor, Michigan • Houston, Texas", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00645333" }, { "nct_id": "NCT00083148", "title": "Irinotecan and Capecitabine in Treating Women With Advanced Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "capecitabine", "type": "DRUG" }, { "name": "irinotecan hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 12, "start_date": "2002-11", "completion_date": "2006-09", "has_results": false, "last_update_posted_date": "2011-03-09", "last_synced_at": "2026-10-31T11:27:40.017Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00083148" }, { "nct_id": "NCT00654355", "title": "Measuring Adherence to Topical Therapy in Children With Atopic Dermatitis and the Impact of a Return Visit", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Atopic Dermatitis" ], "interventions": [ { "name": "tacrolimus ointment", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Wake Forest University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "15 Years", "sex": "ALL", "summary": "2 Years to 15 Years" }, "enrollment_count": 30, "start_date": "2008-04", "completion_date": "2009-09", "has_results": true, "last_update_posted_date": "2018-08-01", "last_synced_at": "2026-10-31T11:27:40.017Z", "location_count": 1, "location_summary": "Winston-Salem, North Carolina", "locations": [ { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00654355" }, { "nct_id": "NCT00405678", "title": "Exercise Intervention Study for Early-Stage Breast Cancer Patients Receiving Neoadjuvant Therapy.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Exercise Training", "type": "BEHAVIORAL" }, { "name": "Chemo only", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 23, "start_date": "2006-09", "completion_date": "2010-09", "has_results": false, "last_update_posted_date": "2014-07-11", "last_synced_at": "2026-10-31T11:27:40.017Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00405678" }, { "nct_id": "NCT05432193", "title": "FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for TReatment of Patients With Select Solid Tumors (FRONTIER)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pancreatic Ductal Adenocarcinoma", "Colorectal Cancer", "Esophageal Cancer", "Melanoma (Skin)", "Soft Tissue Sarcoma", "Head and Neck Squamous Cell Carcinoma", "Cholangiocarcinoma" ], "interventions": [ { "name": "[Ga-68]-PNT6555", "type": "DRUG" }, { "name": "[Lu-177]-PNT6555", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2022-07-13", "completion_date": "2024-10-02", "has_results": false, "last_update_posted_date": "2025-06-25", "last_synced_at": "2026-10-31T11:27:40.017Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05432193" }, { "nct_id": "NCT00588614", "title": "High Risk Screening Breast MR Using a Rapid Imaging Exam", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Breast Cancer" ], "interventions": [], "intervention_types": [], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "25 Years", "maximum_age": "75 Years", "sex": "FEMALE", "summary": "25 Years to 75 Years · Female only" }, "enrollment_count": 140, "start_date": "2006-04", "completion_date": "2011-02", "has_results": false, "last_update_posted_date": "2012-05-30", "last_synced_at": "2026-10-31T11:27:40.017Z", "location_count": 1, "location_summary": "Jacksonville, Florida", "locations": [ { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00588614" }, { "nct_id": "NCT05755347", "title": "Assessing Functional Status Needs Via PRO Measures for Pts With Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Breast Cancer", "Metastasis" ], "interventions": [ { "name": "General health survey questionnaires", "type": "OTHER" }, { "name": "PROMIS Cancer Function Brief 3D profile questionnaires", "type": "OTHER" }, { "name": "FACT-G questionnaires", "type": "OTHER" }, { "name": "Godin Leisure-Time Exercise Questionnaire", "type": "OTHER" }, { "name": "REAP-S questionnaires", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "UNC Lineberger Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": null, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2023-03-17", "completion_date": "2024-02-05", "has_results": false, "last_update_posted_date": "2024-04-11", "last_synced_at": "2026-10-31T11:27:40.017Z", "location_count": 1, "location_summary": "Chapel Hill, North Carolina", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT05755347" }, { "nct_id": "NCT04990726", "title": "Immune Related Toxicity and Symptom Burden in Chronic Cancer Survivors With Melanoma Receiving Adjuvant Immunotherapy With Immune Checkpoint Inhibitors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Clinical Stage III Cutaneous Melanoma AJCC v8", "Pathologic Stage III Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIA Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIB Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIC Cutaneous Melanoma AJCC v8", "Pathologic Stage IIID Cutaneous Melanoma AJCC v8", "Melanoma, Stage II", "Melanoma Stage IV" ], "interventions": [ { "name": "Assessment", "type": "BEHAVIORAL" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "BEHAVIORAL", "PROCEDURE", "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 126, "start_date": "2019-12-05", "completion_date": "2027-02-02", "has_results": false, "last_update_posted_date": "2026-09-18", "last_synced_at": "2026-10-31T11:27:40.017Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04990726" }, { "nct_id": "NCT06982521", "title": "Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "PIK3CA Mutation", "HER2- Negative Breast Cancer", "Hormone Receptor Positive Tumor", "Breast Cancer", "Metastatic Breast Cancer", "Advanced Breast Cancer" ], "interventions": [ { "name": "Zovegalisib", "type": "DRUG" }, { "name": "Capivasertib", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Relay Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 540, "start_date": "2025-08-26", "completion_date": "2031-12-31", "has_results": false, "last_update_posted_date": "2026-10-05", "last_synced_at": "2026-10-31T11:27:40.017Z", "location_count": 52, "location_summary": "Gilbert, Arizona • Beverly Hills, California • Duarte, California + 42 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06982521" } ] }